Biogen Reiterates Byooviz Will Not Be Meaningful In 2022
Launches Outside Of The US Scheduled For Early 2023
Biogen is looking for its ranibizumab biosimilar Byooviz to make a splash in 2023 as it continues to forecast falling biosimilars sales for 2022.
You may also be interested in...
Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.
Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.
Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.